RecruitingPhase 1/2

Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy

China9 participantsStarted 2022-11-30

Plain-language summary

The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of subretinal administration of FT-001 in subjects with biallelic RPE65 mutation-associated retinal dystrophy.

Who can participate

Age range

8 Years – 45 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Subjects who are able to understand and sign the ICF
. Female or male aged 8-45 years old when signing the ICF
. Clinically diagnosed with biallelic RPE65 mutation-associated retinal dystrophy

Exclusion criteria

. Other interfering eye diseases
. Presence of any systemic or ocular disease that can cause or likely to cause vision loss
. There is evidence of obviously uncontrolled concomitant diseases
. Known to have active or suspected autoimmune diseases
. With active systemic infection under treatment
. Pregnant or lactating women
. Other conditions unsuitable for the study as determined by the investigator

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Safety of FT-001(incidence of ocular and non-ocular AEs and SAEs)

Timeframe: 52 weeks

Trial details

NCT IDNCT05858983

SponsorFrontera Therapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-11-30

Contact for this trial

Xinyan Li

+86-021-58206061 Xinyan.li@fronteratherapeutics.com

View on ClinicalTrials.gov More Biallelic RPE65 Mutation-associated Retinal Dystrophy trials